Search

Your search keyword '"Lau, Johnson Y. N."' showing total 347 results
Start Over Author "Lau, Johnson Y. N."
347 results on '"Lau, Johnson Y. N."'

2. Human Genome Project

Author

Tsui, Nancy B. Y., Lau, Johnson Y. N., Lau, Lok Ting, Section editor, Gu, Danan, editor, and Dupre, Matthew E., editor

Published
2021
Full Text
View/download PDF

3. Genotype

Author

Tsui, Nancy B. Y., Lau, Johnson Y. N., Lau, Lok Ting, Section editor, Gu, Danan, editor, and Dupre, Matthew E., editor

Published
2021
Full Text
View/download PDF

4. Mutation

Author

Tsui, Nancy B. Y., Lau, Johnson Y. N., Lau, Lok Ting, Section editor, Gu, Danan, editor, and Dupre, Matthew E., editor

Published
2021
Full Text
View/download PDF

5. Phenotype

Author

Tsui, Nancy B. Y., Lau, Johnson Y. N., Lau, Lok Ting, Section editor, Gu, Danan, editor, and Dupre, Matthew E., editor

Published
2021
Full Text
View/download PDF

8. Genotype

Author

Tsui, Nancy B. Y., primary and Lau, Johnson Y. N., additional

Published
2019
Full Text
View/download PDF

9. Mutation

Author

Tsui, Nancy B. Y., primary and Lau, Johnson Y. N., additional

Published
2019
Full Text
View/download PDF

11. Gut microbiota-derived tryptamine and phenethylamine impair insulin sensitivity in metabolic syndrome and irritable bowel syndrome

Author

Zhai, Lixiang, primary, Xiao, Hai-Tao, additional, Lin, Chengyuan, additional, Wong, Hoi Leong Xavier, additional, Lam, Yan Y., additional, Gong, Mengxue, additional, Wu, Guojun, additional, Ning, Ziwan, additional, Huang, Chunhua, additional, Zhang, Yijing, additional, Yang, Chao, additional, Luo, Jingyuan, additional, Zhang, Lu, additional, Zhao, Ling, additional, Zhang, Chenhong, additional, Lau, Johnson Y. N., additional, Lu, Aiping, additional, Lau, Lok-Ting, additional, Jia, Wei, additional, Zhao, Liping, additional, and Bian, Zhao-xiang, additional

Published
2023
Full Text
View/download PDF

13. Jinhua Qinggan granules for non-hospitalized COVID-19 patients: A double-blind, placebo-controlled, and randomized controlled trial

Author

Shah, Muhammad Raza, Fatima, Samreen, Khan, Sehrosh Naz, Ullah, Shafi, Himani, Gulshan, Wan, Kelvin, Lin, Timothy, Lau, Johnson Y. N., Liu, Qingquan, and Lam, Dennis S. C.

Subjects
General Medicine
Abstract

BackgroundKey findings from the World Health Organization Expert Meeting on Evaluation of Traditional Chinese Medicine (TCM) in treating coronavirus disease 2019 (COVID-19) reported that TCMs are beneficial, particularly for mild-to-moderate cases. The efficacy of Jinhua Qinggan granules (JHQG) in COVID-19 patients with mild symptoms has yet to be clearly defined.MethodsWe conducted a phase 2/3, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of treatment with JHQG in mild, non-hospitalized, laboratory-confirmed COVID-19 patients. Participants were randomly assigned to receive 5 g/sacket of JHQG or placebo granules orally thrice daily for 10 days. The primary outcomes were the improvement in clinical symptoms and a proportion tested negative on viral polymerase chain reaction (PCR) after treatment. Secondary outcomes were the time to recover from clinical symptoms and changes in white blood cells (WBC) and acute phase reactants (C-reactive protein (CRP) and ferritin) on the 10th day after treatment initiation.ResultsA total of 300 patients were randomly assigned to receive JHQG (150 patients) and placebo (150 patients). Baseline characteristics were similar in the two groups. In the modified intention-to-treat analysis, JHQG showed greater clinical efficacy (82.67%) on the 10th day of the trial compared with the placebo group (10.74%; rate difference: 71.93%; 95% CI 64.09–79.76). The proportion of patients with a negative PCR after treatment was comparable (rate difference: −4.67%; 95% CI −15.76 to 6.42). In contrast, all changes in WBC, ferritin, and CRP levels showed a statistically significant decline in JHQG (P ≤ 0.044) after treatment, but not the latter in placebo (P = 0.077). The median time to recovery of COVID-19-related symptoms including cough, sputum, sore throat, dyspnea, headache, nasal obstruction, fatigue, and myalgia was shorter in the JHQG group compared to the placebo group (P < 0.001 for all). Three patients experienced mild-to-moderate adverse events (AEs) duringthe treatment period in the JHQG group. Findings were similar between the modified intention-to-treat and the per-protocol analysis that included only patients who reported 100% adherence to the assigned regimen.ConclusionBased on the time to recover from the COVID-19-related symptoms and AEs, it is concluded that JHQG is a safe and effective TCM for symptomatic relief of patients with mild COVID-19. A symptomatic improvement in the JHQG group patients was observed and JHQG use would have important public health implications in such patients.Clinical Trial RegistrationThe Trial was prospectively registered on www.clinicaltrials.gov with registration number: NCT04723524.

Published
2022

16. Hepatitis C and G

Author

Bhardwaj, Gabu, Davis, Gary L., Lau, Johnson Y. N., Wu, George Y., editor, and Israel, Jonathan, editor

Published
1998
Full Text
View/download PDF

19. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2

Author

Yeung, Man-Lung, Yao, Yanfeng, Jia, Lilong, Chan, Jasper F. W., Chan, Kwok-Hung, Cheung, Kwok-Fan, Chen, Honglin, Poon, Vincent K. M., Tsang, Alan K. L., To, Kelvin K.W., Yiu, Ming-Kwong, Teng, Jade L. L., Chu, Hin, Zhou, Jie, Zhang, Qing, Deng, Wei, Lau, Susanna K. P., Lau, Johnson Y. N., Woo, Patrick C. Y., Chan, Tak-Mao, Yung, Susan, Zheng, Bo-Jian, Jin, Dong-Yan, Mathieson, Peter W., Qin, Chuan, and Yuen, Kwok-Yung

Published
2016
Full Text
View/download PDF

21. GB Virus C/Hepatitis G Virus Infection in Southern China

Author

Wu, Rong-Rong, Mizokami, Masashi, Cao, Kun, Nakano, Tatsunori, Ge, Xian-Min, Wang, Su-Seng, Orito, Etsuro, Ohba, Ken-ichi, Mukaide, Motokazu, Hikiji, Kazumasa, Lau, Johnson Y. N., and Iino, Shiro

Published
1997

23. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

Author

Crotty, Shane, Maag, David, Arnold, Jamie J., Zhong, Weidong, Lau, Johnson Y. N., Hong, Zhi, Andino, Raul, and Cameron, Craig E.

Subjects
Hepatitis C -- Diagnosis, Hepatitis C -- Drug therapy, Hepatitis C -- Research, Hepatitis C -- Causes of, RNA viruses -- Health aspects, RNA viruses -- Control, Ribavirin -- Dosage and administration
Abstract

The ribonucleoside analog ribavirin (1-[beta]-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) shows antiviral activity against a variety of RNA viruses and is used in combination with interferon-[alpha] to treat hepatitis C virus infection. Here we show in vitro use of ribavirin triphosphate by a model viral RNA polymerase, poliovirus 3D[sup.pol]. Ribavirin incorporation is mutagenic, as it templates incorporation of cytidine and uridine with equal efficiency. Ribavirin reduces infectious poliovirus production to as little as 0.00001% in cell culture. The antiviral activity of ribavirin correlates directly with its mutagenic activity. These data indicate that ribavirin forces the virus into `error catastrophe&apos;. Thus, mutagenic ribonucleosides may represent an important class of anti-RNA virus agents., Author(s): Shane Crotty [1]; David Maag [2]; Jamie J. Arnold [2]; Weidong Zhong [3]; Johnson Y. N. Lau [3]; Zhi Hong [3]; Raul Andino [1]; Craig E. Cameron (corresponding author) [...]

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results